138926-19-9 | Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt, hydrate (1:1:1)

Packsize	Purity	Availability	Price	Discounted Price
1g	98%	in stock	$44.00	$31.00
5g	98%	in stock	$114.00	$80.00
10g	98%	in stock	$211.00	$148.00
25g	98%	in stock	$387.00	$271.00
100g	98%	in stock	$1,132.00	$793.00

Description

• Catalog Number: AA59226
• Chemical Name: Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt, hydrate (1:1:1)
• CAS Number: 138926-19-9
• Molecular Formula: C9H24NNaO8P2
• Molecular Weight: 359.2261
• MDL Number: MFCD00912167
• SMILES: CCCCCN(CCC(P(=O)(O)O)(P(=O)(O)[O-])O)C.[Na+].O

Computed Properties

• Complexity: 377
• Covalently-Bonded Unit Count: 3
• Heavy Atom Count: 21
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 5
• Rotatable Bond Count: 9
• Undefined Atom Stereocenter Count: 1

Literature

• Bioactivity of Ti-6Al-4V alloy implants treated with ibandronate after the formation of the nanotube TiO2 layer.

  Journal of biomedical materials research. Part B, Applied biomaterials 20121101

• Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw.

  Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20121001

• Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.

  The Journal of clinical endocrinology and metabolism 20121001

• Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain.

  Medicina oral, patologia oral y cirugia bucal 20120901

• Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.

  Journal of bone and mineral metabolism 20120901

• Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120801

• Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.

  Scandinavian journal of rheumatology 20120801

• Monitoring of bone turnover markers does not improve persistence with ibandronate treatment.

  Joint, bone, spine : revue du rhumatisme 20120701

• Bisphosphonate-related osteonecrosis of the mandible secondary to postural pressure.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120701

• Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.

  Arthritis care & research 20120701

• Once-monthly oral ibandronate treatment in an adolescent with recurrent fractures and inadequately low bone mass.

  Journal of paediatrics and child health 20120701

• Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120601

• Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120601

• Gastrointestinal bleeding following intravenous ibandronate administration.

  Journal of pharmacy practice 20120601

• Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.

  Transplantation proceedings 20120601

• Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120514

• [Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection].

  Se pu = Chinese journal of chromatography 20120401

• Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model.

  Calcified tissue international 20120301

• Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).

  Die Pharmazie 20120301

• Question: In postmenopausal women with osteoporosis is once monthly oral ibandronate (150 mg) therapy preferred to once weekly oral bisphosphonate therapy.

  The Journal of the Oklahoma State Medical Association 20120301

• Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.

  Transplantation 20120215

• Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.

  Clinical oral investigations 20120201

• Counting touching cell nuclei using fast ellipse detection to assess in vitro cell characteristics: a feasibility study.

  Clinical oral investigations 20120201

• The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

  Clinical oral investigations 20120201

• Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120201

• [Pelvic pain in the athlete: not always that simple...].

  Revue medicale suisse 20120125

• Effect of monthly ibandronate on hip structural geometry in men with low bone density.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101

• Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.

  Bone 20120101

• Possible role of oral ibandronate administration in Osteonecrosis of the Jaw: a case report.

  International journal of immunopathology and pharmacology 20120101

• Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate.

  Onkologie 20120101

• Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.

  Onkologie 20120101

• Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study.

  American journal of nephrology 20120101

• Bisphosphonates for osteoporosis in primary biliary cirrhosis.

  The Cochrane database of systematic reviews 20111207

• Daily or monthly ibandronate prevents or restores deteriorations of bone mass, architecture, biomechanical properties and markers of bone turnover in androgen-deficient aged rats.

  The aging male : the official journal of the International Society for the Study of the Aging Male 20111201

• Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.

  Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20111201

• Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.

  Breast (Edinburgh, Scotland) 20111201

• Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.

  Bone 20111201

• Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.

  Clinical rheumatology 20111201

• Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women.

  Biopharmaceutics & drug disposition 20111101

• The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20111001

• Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.

  Journal of managed care pharmacy : JMCP 20111001

• Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.

  Anticancer research 20111001

• Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta.

  Chinese medical journal 20111001

• Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.

  American journal of therapeutics 20110901

• A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.

  American journal of therapeutics 20110901

• Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.

  The Korean journal of internal medicine 20110901

• Administration of sodium ibandronate in the treatment of complicated giant cell tumor of the spine.

  Spine 20110801

• Non-surgical management of stage 3 biphosphonate-related oroantral fistula.

  The British journal of oral & maxillofacial surgery 20110701

• Effect of bisphosphonates on anodized and heat-treated titanium surfaces: an animal experimental study.

  Journal of periodontology 20110701

• [Assessment of volumetric bone mineral density and geometry for hip with clinical CT device].

  Clinical calcium 20110701

• Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.

  International journal of clinical oncology 20110601

• Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline.

  Journal of clinical pharmacy and therapeutics 20110601

• Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.

  Journal of gastrointestinal and liver diseases : JGLD 20110601

• Commentary on an article by Jacob S. Vandermeer et al.: 'Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head. A combined therapy that stimulates bone formation and decreases femoral head deformity'.

  The Journal of bone and joint surgery. American volume 20110518

• Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity.

  The Journal of bone and joint surgery. American volume 20110518

• Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: a microarchitectural and mechanical study.

  Bone 20110501

• Low-magnitude high-frequency vibration (LMHFV) enhances bone remodeling in osteoporotic rat femoral fracture healing.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20110501

• Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301

• Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.

  Oral diseases 20110301

• Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients--a prospective study.

  Pediatric transplantation 20110301

• Treatment of lumbar pars interarticularis stress injuries in athletes with intravenous bisphosphonates: five case studies.

  Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine 20110301

• The treatment of symptomatic osteoporotic spinal compression fractures.

  The Journal of the American Academy of Orthopaedic Surgeons 20110301

• Stability indicating ion chromatography method for the simultaneous determination of ibandronate sodium drug substance and its impurities.

  Journal of pharmaceutical and biomedical analysis 20110220

• Osteonecrosis of the jaw and the role of macrophages.

  Journal of the National Cancer Institute 20110202

• Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.

  Clinical oral investigations 20110201

• Bisphosphonates inhibit phosphorylation of signal transducer and activator of transcription 3 and expression of suppressor of cytokine signaling 3: implications for their effects on innate immune function and osteoclastogenesis.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20110201

• Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.

  World journal of gastroenterology 20110121

• Ibandronate promotes osteogenic differentiation of periodontal ligament stem cells by regulating the expression of microRNAs.

  Biochemical and biophysical research communications 20110107

• Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.

  Acta oncologica (Stockholm, Sweden) 20110101

• Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function.

  Pediatric nephrology (Berlin, Germany) 20110101

• [Ibandronate].

  Clinical calcium 20110101

• When do bisphosphonates make the most sense?

  The Journal of family practice 20110101

• The role of i.v. ibandronate administration in osteoporosis therapy.

  Endokrynologia Polska 20110101

• Adverse cutaneous drug reactions to ibandronate.

  European journal of dermatology : EJD 20110101

• [The role of i.v. ibandronate administration in osteoporosis therapy].

  Endokrynologia Polska 20110101

• [Osteonecrosis of the jaw associated with oral treatment with ibandronate].

  Anales del sistema sanitario de Navarra 20110101

• Drug-drug interaction study between a novel oral ibandronate formulation and metformin.

  Arzneimittel-Forschung 20110101

• Prospective clinical study of once monthly ibandronate in the treatment of osteoporosis and prevention of fractures in postmenopausal women: ORPHEUM Study.

  Srpski arhiv za celokupno lekarstvo 20110101

• Adherence to bisphosphonate therapy in postmenopausal osteoporotic women.

  Folia medica 20110101

• Preparation and properties of new co-crystals of ibandronate with gluco- or galactopyranoside derivatives.

  Molecules (Basel, Switzerland) 20101208

• Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.

  Clinical breast cancer 20101201

• Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20101101

• Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.

  Orthopedics 20101011

• Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20101001

• Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes.

  Clinical biochemistry 20101001

• Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.

  Calcified tissue international 20101001

• The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate.

  Journal of cellular biochemistry 20100901

• Successful treatment of SAPHO syndrome with ibandronate.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20100801

• Treatment of osteoporosis after liver transplantation with ibandronate.

  Transplant international : official journal of the European Society for Organ Transplantation 20100701

• Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100601

• Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.

  Bone 20100601

• Postmenopausal osteoporosis: another approach to management.

  The Journal of family practice 20100601

• [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].

  Ginecologia y obstetricia de Mexico 20100601

• An in vitro assay to measure targeted drug delivery to bone mineral.

  ChemMedChem 20100503

• Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.

  Journal of bone and mineral metabolism 20100501

• Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials.

  International journal of clinical practice 20100501

• How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.

  Journal of the American Dental Association (1939) 20100501

• Efficacy and safety of monthly ibandronate in men with low bone density.

  Bone 20100401

• Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs).

  Bioorganic & medicinal chemistry 20100401

• Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study.

  Bone 20100301

• Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.

  Current medical research and opinion 20100301

• Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.

  Journal of medical economics 20100301

• Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100201

• Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.

  Journal of chemotherapy (Florence, Italy) 20100201

• Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100101

• Management of symptomatic bone metastases from breast cancer with concomitant use of external radiotherapy and ibandronate: results of a prospective, pilot study.

  The breast journal 20100101

• The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20100101

• Efficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density--ESTHER study.

  Srpski arhiv za celokupno lekarstvo 20100101

• Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.

  Journal of cancer research and therapeutics 20100101

• Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.

  BMC musculoskeletal disorders 20100101

• Challenges in clinical patient management.

  Cancer investigation 20100101

• Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.

  Onkologie 20100101

• Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.

  Endocrine research 20100101

• Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid.

  Arthritis research & therapy 20100101

• Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study.

  Cardiology 20100101

• The efficiency of Bonviva (Ibadronate) in women with pre-post menopause.

  Medicinski arhiv 20100101

• Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.

  Prilozi 20100101

• Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells.

  The Journal of international medical research 20100101

• Metronomic administration of ibandronate and its anti-angiogenic effects in vitro.

  Microvascular research 20091201

• Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

  Current medical research and opinion 20091201

• Review of osteoporosis pharmacotherapy for geriatric patients.

  The American journal of geriatric pharmacotherapy 20091201

• Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110

• Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.

  European journal of cancer care 20091101

• Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.

  Calcified tissue international 20091101

• A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates.

  Journal of endodontics 20091101

• High-throughput HPLC-MS/MS method to determine ibandronate in human plasma for pharmacokinetic applications.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001

• [Anti-fracture efficacy of intravenous ibandronate: how to translate epidemiological studies into daily clinical practice].

  Revue medicale de Liege 20091001

• Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090901

• Ibandronate reduces endogenous reactive oxygen species levels in cultured prostate cancer and endothelial cells.

  Microvascular research 20090901

• Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.

  Women's health (London, England) 20090901

• Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series.

  Onkologie 20090901

• [Emergencies in hematology and oncology].

  Deutsche medizinische Wochenschrift (1946) 20090901

• [Diagnosis and treatment of bone marrow edema syndrome of the hip and differential diagnosis from avascular necrosis of femoral head].

  Zhongguo gu shang = China journal of orthopaedics and traumatology 20090901

• Safety and antisorptive power of Ibandronate applied in the real-life setting.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090901

• Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women.

  International journal of rheumatic diseases 20090901

• Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.

  Current medical research and opinion 20090801

• Pricey osteoporosis remedy doesn't beat older drugs.

  Consumer reports 20090801

• Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090701

• Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.

  Journal of women's health (2002) 20090701

• Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.

  Clinical therapeutics 20090701

• Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20090601

• Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.

  Bone 20090501

• Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.

  Southern medical journal 20090501

• [Drugs under development for osteoporosis ].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.

  The Annals of pharmacotherapy 20090401

• Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

  Clinical therapeutics 20090401

• Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

  Bone 20090301

• Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.

  Clinical rheumatology 20090301

• Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.

  Bone 20090301

• The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats.

  Biomaterials 20090301

• Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090201

• Plain film and CBCT findings in a case of bisphosphonate-related osteonecrosis of the jaw.

  Quintessence international (Berlin, Germany : 1985) 20090201

• Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

  The American journal of medicine 20090201

• Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

  Cancer investigation 20090201

• Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.

  The Journal of clinical endocrinology and metabolism 20090101

• Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20090101

• [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].

  Clinical calcium 20090101

• Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.

  Genome biology 20090101

• Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.

  Clinical interventions in aging 20090101

• Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?

  Acta oncologica (Stockholm, Sweden) 20090101

• Dendritic multishell architectures for drug and dye transport.

  Journal of controlled release : official journal of the Controlled Release Society 20081218

• Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.

  Journal of cancer research and clinical oncology 20081201

• Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates.

  Journal of surgical oncology 20081201

• Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.

  Expert opinion on pharmacotherapy 20081201

• [Bisphosphonates for osseus invasion caused by bronchial carcinoma].

  Deutsche medizinische Wochenschrift (1946) 20081101

• Ibandronate: is there an effect on nonvertebral fractures?

  Clinical rheumatology 20081001

• An open-label pilot trial of ibandronate for complex regional pain syndrome.

  The Clinical journal of pain 20081001

• Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081001

• [Ibandronate in the treatment of postmenopausal osteoporosis].

  Lege artis medicinae : uj magyar orvosi hirmondo 20081001

• Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.

  Journal of pain and symptom management 20080901

• Acute phase reaction with intravenous ibandronate.

  The American journal of medicine 20080901

• Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.

  Current osteoporosis reports 20080901

• Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

  The American journal of managed care 20080901

• [Update on treatment of postmenopausal osteoporosis].

  Revue medicale de Bruxelles 20080901

• Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.

  Clinical rheumatology 20080801

• [Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].

  Clinical calcium 20080801

• Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Identification of novel bone-specific molecular targets of binge alcohol and ibandronate by transcriptome analysis.

  Alcoholism, clinical and experimental research 20080701

• Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20080701

• Ibandronate in profile: drug characteristics and clinical efficacy.

  Expert opinion on drug metabolism & toxicology 20080701

• Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.

  Toxicology in vitro : an international journal published in association with BIBRA 20080601

• Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.

  Postgraduate medical journal 20080601

• Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).

  Joint, bone, spine : revue du rhumatisme 20080501

• Ibandronate in benign bone disease.

  Reviews on recent clinical trials 20080501

• Quarterly intravenous ibandronate for postmenopausal osteoporosis.

  Women's health (London, England) 20080501

• Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain.

  European journal of pain (London, England) 20080401

• Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.

  Clinical therapeutics 20080401

• A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.

  Breast cancer research and treatment 20080301

• Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301

• Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.

  Current medical research and opinion 20080301

• Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.

  The Journal of rheumatology 20080301

• [Osteonecrosis of the jaw developing during bisphosphonate treatment].

  Magyar onkologia 20080301

• Reply to the article 'oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases' by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).

  Annals of oncology : official journal of the European Society for Medical Oncology 20080201

• [Prescription of bisphosphonates in prostate cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080201

• Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.

  Current medical research and opinion 20080101

• Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.

  Current medical research and opinion 20080101

• Vertebral fracture diagnosis in the multinational BONE study of oral ibandronate: quality management in radiology.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20080101

• Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.

  Breast cancer research : BCR 20080101

• Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.

  PharmacoEconomics 20080101

• Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.

  PharmacoEconomics 20080101

• [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].

  Recenti progressi in medicina 20080101

• Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naïve population.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20080101

• Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.

  The Journal of international medical research 20080101

• Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.

  Urologia internationalis 20080101

• Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat.

  Journal of bone and mineral metabolism 20080101

• Treatment of reduced bone density with ibandronate in dialysis patients.

  Journal of nephrology 20080101

• Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.

  Current clinical pharmacology 20080101

• Osteonecrosis of the jaw in a patient treated with ibandronate.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20080101

• [Hypercalcaemic crisis and acute renal failure due to primary hyperparathyroidism].

  Deutsche medizinische Wochenschrift (1946) 20080101

• Ibandronate: a review of its use in the management of postmenopausal osteoporosis.

  Drugs 20080101

• Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.

  Clinical and experimental rheumatology 20080101

• Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.

  Journal of cutaneous pathology 20071201

• Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.

  Minerva endocrinologica 20071201

• Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients.

  Acta orthopaedica 20071201

• Linköping University Medical Dissertation No. 1033. Following the mevalonate pathway to bone heal alley.

  Acta orthopaedica. Supplementum 20071201

• [New bone density conservation agents for osteoporosis under research and development: Ibandronate].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.

  European journal of cancer care 20071101

• Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.

  Annals of the New York Academy of Sciences 20071101

• Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats.

  Bone 20071001

• Osteoporosis: non-hormonal treatment.

  Climacteric : the journal of the International Menopause Society 20071001

• [The benefit from ibandronate in the treatment of postmenopausal osteoporosis].

  Vnitrni lekarstvi 20071001

• Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates.

  Chemical research in toxicology 20070901

• Osteoporosis medication profile preference: results from the PREFER-US study.

  Health expectations : an international journal of public participation in health care and health policy 20070901

• [Adjuvant therapy of locally advanced prostate carcinoma with ibandronate].

  Der Urologe. Ausg. A 20070901

• Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function.

  Journal of clinical pharmacology 20070801

• Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.

  British dental journal 20070728

• Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.

  Annals of the rheumatic diseases 20070701

• Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• New and emerging treatments for osteoporosis.

  Current opinion in rheumatology 20070701

• Pharmacological treatment of osteoporosis for people over 70.

  Aging clinical and experimental research 20070601

• Validation of a capillary electrophoresis method for the analysis of ibandronate related impurities.

  Journal of pharmaceutical and biomedical analysis 20070509

• Bisphosphonates. A cornerstone of osteoporosis treatment.

  Mayo Clinic women's healthsource 20070501

• [Nurse's role in the home management of patients with breast cancer and bone metastases].

  Soins; la revue de reference infirmiere 20070501

• Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs.

  Bone 20070301

• Use of intravenous bisphosphonates in osteoporosis.

  Current osteoporosis reports 20070301

• Prevention and treatment of glucocorticoid-induced osteoporosis.

  Current osteoporosis reports 20070301

• Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.

  Clinical interventions in aging 20070301

• Differential effects of bisphosphonates on breast cancer cell lines.

  Cancer letters 20070208

• Effects of ibandronate on bone quality: preclinical studies.

  Bone 20070201

• Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.

  Bone 20070201

• Drug approvals.

  The Nurse practitioner 20070201

• Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment.

  International journal of radiation oncology, biology, physics 20070101

• Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20070101

• [Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate].

  Clinical calcium 20070101

• The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model.

  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20070101

• Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.

  Journal of bone and mineral metabolism 20070101

• Clinical usefulness of bisphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers.

  The International journal of biological markers 20070101

• A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate.

  Clinical & experimental metastasis 20070101

• Safety considerations with bisphosphonates for the treatment of osteoporosis.

  Drug safety 20070101

• A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover.

  Clinical and experimental rheumatology 20070101

• [Does ibandronate (Bonviva) have an impact on non-vertebral fractures?].

  Reumatizam 20070101

• Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.

  International journal of clinical pharmacology and therapeutics 20061201

• Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.

  Current medical research and opinion 20061201

• Bisphosphonates.

  Annals of the New York Academy of Sciences 20061201

• Compliance with treatment for osteoporosis.

  Lancet (London, England) 20061111

• Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate.

  Kidney international 20061101

• Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?

  Kidney international 20061101

• [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].

  Revue medicale de Liege 20061101

• Ibandronate (boniva) offers new options for osteoporosis.

  The Nurse practitioner 20061001

• Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis.

  Current drug metabolism 20061001

• Parathyromatosis and the challenge of treatment.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20060901

• [DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?].

  Zeitschrift fur Rheumatologie 20060901

• Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.

  International journal of clinical practice 20060801

• Rinsing morcellised bone grafts with bisphosphonate solution prevents their resorption. A prospective randomised double-blinded study.

  The Journal of bone and joint surgery. British volume 20060801

• New drugs 06, part II.

  Nursing 20060801

• Intravenous ibandronate (Boniva).

  The Medical letter on drugs and therapeutics 20060801

• Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head.

  Bone 20060701

• Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronate.

  Annals of the rheumatic diseases 20060701

• Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.

  European journal of cancer care 20060701

• Osseointegration of cementless implants with different bisphosphonate regimens.

  Clinical orthopaedics and related research 20060601

• Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.

  Arthritis and rheumatism 20060601

• Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate.

  Current medical research and opinion 20060601

• Fracture prevention in postmenopausal women.

  Clinical evidence 20060601

• Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.

  Annals of the rheumatic diseases 20060501

• Extracellular matrix changes in knee joint cartilage following bone-active drug treatment.

  Cell and tissue research 20060501

• Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.

  Pharmacotherapy 20060501

• What's new in clinical pharmacology and therapeutics.

  WMJ : official publication of the State Medical Society of Wisconsin 20060501

• Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.

  Maturitas 20060420

• Adherence, patient preference and dosing frequency: understanding the relationship.

  Bone 20060401

• Beyond daily dosing: clinical experience.

  Bone 20060401

• Ibandronate: pharmacology and preclinical studies.

  Bone 20060401

• Once-monthly dosing: an effective step forward.

  Bone 20060401

• Preventing osteoporosis-related fractures: an overview.

  The American journal of medicine 20060401

• Injectable drug approved for osteoporosis.

  Health news (Waltham, Mass.) 20060401

• Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.

  Clinical therapeutics 20060401

• Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans.

  Annals of the New York Academy of Sciences 20060401

• Drug insight: Bisphosphonates for postmenopausal osteoporosis.

  Nature clinical practice. Endocrinology & metabolism 20060401

• Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase.

  Journal of the American Chemical Society 20060322

• [Therapy of hypercalcemia with ibandronate in case of acute renal failure].

  Der Internist 20060301

• Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.

  Current osteoporosis reports 20060301

• A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060201

• Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.

  Bone 20060201

• Strategies for the prevention and treatment of osteoporosis during early postmenopause.

  American journal of obstetrics and gynecology 20060201

• Rapid pain relief and remission of sternocostoclavicular hyperostosis after intravenous ibandronate therapy.

  Journal of bone and mineral metabolism 20060101

• Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.

  Breast cancer research : BCR 20060101

• [Ibandronate once a month].

  Medizinische Monatsschrift fur Pharmazeuten 20060101

• Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.

  Drugs 20060101

• Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20060101

• Rapid infusion of ibandronate in lung cancer patients with bone metastases.

  Anticancer research 20060101

• Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.

  Drugs 20060101

• Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.

  Clinical & experimental metastasis 20060101

• Intravenous ibandronate: in the treatment of osteoporosis.

  Drugs 20060101

• Ibandronate: its role in metastatic breast cancer.

  The oncologist 20060101

• Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports.

  Acta haematologica 20060101

• Non-ulcerating calcific uremic arteriolopathy skin lesion treated successfully with intravenous ibandronate.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20060101

• Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

  Drug safety 20060101

• Intravenous ibandronate in the treatment of osteoporosis: profile report.

  Drugs & aging 20060101

• Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience.

  Clinical drug investigation 20060101

• Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.

  Clinical drug investigation 20060101

• [The role of ibandronate in the daily oncological practice].

  Magyar onkologia 20060101

• [Ibandronate].

  Reumatizam 20060101

• Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20051201

• Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20051201

• Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?

  Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20051201

• Newer drug treatments: their effects on fracture prevention.

  Best practice & research. Clinical rheumatology 20051201

• Acute renal effects of intravenous bisphosphonates in the rat.

  Basic & clinical pharmacology & toxicology 20051201

• Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

  Current medical research and opinion 20051201

• Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.

  Clinical breast cancer 20051201

• Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.

  Bone 20051101

• High dosage treatment of nitrogen-containing bisphosphonate ibandronate is required for osseointegration of cementless metal implants.

  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20051101

• S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.

  Clinical advances in hematology & oncology : H&O 20051101

• Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis.

  Bone 20051001

• Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.

  The Journal of rheumatology 20051001

• Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.

  Expert opinion on pharmacotherapy 20051001

• Review of treatment modalities for postmenopausal osteoporosis.

  Southern medical journal 20051001

• Ibandronate: efficacy in the treatment of metastatic bone disease.

  Future oncology (London, England) 20051001

• Analytical methods for the quantification of ibandronate in body fluids and bone.

  Journal of pharmaceutical and biomedical analysis 20050901

• Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.

  The Journal of clinical endocrinology and metabolism 20050901

• The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats.

  Bone 20050801

• Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050801

• Ibandronate (Boniva): a new oral bisphosphonate.

  Obstetrics and gynecology 20050801

• Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.

  Clinical therapeutics 20050801

• A new option for osteoporosis.

  The Johns Hopkins medical letter health after 50 20050701

• New therapeutic agents for the treatment of bone diseases.

  Expert opinion on biological therapy 20050601

• Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.

  Clinical breast cancer 20050601

• First once-a-month osteoporosis pill approved.

  Harvard women's health watch 20050601

• A bright future for osteoporosis treatment.

  Drug news & perspectives 20050601

• Longer-lasting osteoporosis drugs sought.

  JAMA 20050525

• Bisphosphonates in breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• Changes in bone structure after augmentation cystoplasty in chronic uraemic rats.

  BJU international 20050501

• The issue of renal safety of zoledronic acid from a nephrologist's point of view.

  The oncologist 20050501

• 'Safety and convenience of a 15-minute infusion of zoledronic acid': not so safe.

  The oncologist 20050501

• New drugs and dosage forms.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050501

• Ibandronate (Boniva): a new oral bisphosphonate.

  The Medical letter on drugs and therapeutics 20050425

• Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050301

• Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs.

  The Journal of bone and joint surgery. American volume 20050301

• Oral antiresorptive therapy.

  Current rheumatology reports 20050301

• Rapid prevention of vertebral fractures associated with osteoporosis.

  Orthopedics 20050301

• Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

  Current medical research and opinion 20050301

• Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050201

• Explicit solutions for a class of indirect pharmacodynamic response models.

  Computer methods and programs in biomedicine 20050201

• Ibandronate in metastatic bone disease: a review of preclinical data.

  Anti-cancer drugs 20050201

• Oral ibandronic acid.

  IDrugs : the investigational drugs journal 20050201

• [Ibandronate as a new therapeutic agent for osteoporosis].

  Clinical calcium 20050101

• The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.

  Oncology 20050101

• Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.

  Treatments in endocrinology 20050101

• [Monthly tablet].

  Krankenpflege Journal 20050101

• New drugs: entecavir, ibandronate sodium, and pegaptanib sodium.

  Journal of the American Pharmacists Association : JAPhA 20050101

• Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.

  Treatments in endocrinology 20050101

• Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients.

  Anticancer research 20050101

• [Postmenopausal osteoporosis].

  Krankenpflege Journal 20050101

• Efficacy of ibandronate in metastatic bone disease: review of clinical data.

  The oncologist 20050101

• Renal safety of ibandronate.

  The oncologist 20050101

• Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.

  Current pharmaceutical design 20050101

• Once-monthly ibandronate.

  Treatments in endocrinology 20050101

• High bone-binding capacity of ibandronate in hemodialysis patients.

  International journal of clinical pharmacology research 20050101

• [Zoledronic acid and bone pathology in the course of neoplasia. Part I].

  Tumori 20050101

• [Monthly tablet in postmenopausal osteoporosis].

  Krankenpflege Journal 20050101

• Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20041201

• A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.

  British journal of clinical pharmacology 20041201

• Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.

  Expert review of anticancer therapy 20041201

• Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.

  Seminars in oncology 20041201

• [Clinical trial on ibandronate in patients with tumor-associated hypercalcemia].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20041201

• Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.

  Clinical therapeutics 20041201

• Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20041101

• Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.

  Oncology reports 20041101

• Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.

  Expert opinion on pharmacotherapy 20041101

• Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20041001

• Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.

  Pain 20041001

• The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041001

• Targeting Breast Cancer with Care. Proceedings of a meeting. Prague, Czech Republic, February 2004.

  Seminars in oncology 20041001

• Ibandronate reduces skeletal morbidity in patients with breast cancer.

  Seminars in oncology 20041001

• Ibandronate in metastatic bone pain.

  Seminars in oncology 20041001

• Managing metastatic bone disease: three case studies.

  Seminars in oncology 20041001

• The RIB trial.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20041001

• Systemic and local ibandronate enhance screw fixation.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20040901

• Ibandronate: a clinical pharmacological and pharmacokinetic update.

  Journal of clinical pharmacology 20040901

• Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040901

• [Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].

  Der Urologe. Ausg. A 20040901

• In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.

  Anti-cancer drugs 20040901

• Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040801

• Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.

  Bone 20040701

• Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.

  European journal of cancer (Oxford, England : 1990) 20040701

• Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20040601

• Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells.

  International journal of oncology 20040501

• Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040501

• Ibandronate and prevention of postmenopausal osteoporosis.

  Annals of the rheumatic diseases 20040501

• Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040501

• Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040501

• Efficacy and safety of ibandronate given by intravenous injection once every 3 months.

  Bone 20040501

• Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.

  Bone 20040501

• [Bone metastases in breast carcinoma. Bisphosphonate protects from complications].

  MMW Fortschritte der Medizin 20040401

• Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.

  British journal of cancer 20040322

• Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20040301

• Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040301

• Nephrotoxicity of third-generation, intravenous bisphosphonates.

  Toxicology 20040301

• [Ibandronate].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat.

  The Journal of biological chemistry 20040116

• Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040101

• Safety and convenience of a 15-minute infusion of zoledronic acid.

  The oncologist 20040101

• New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate.

  Journal of pharmacological and toxicological methods 20040101

• [Ibandronate: keep life in motion].

  Tumori 20040101

• [Oral and parenteral forms of aminobisphosphonate].

  Krankenpflege Journal 20040101

• [AIOM Conference 2004. Endocrine therapy and management of patients with bone metastasis of breast cancer].

  Tumori 20040101

• [ESMO Conference 2004. Ibandronate in the treatment of bone metastasis].

  Tumori 20040101

• Ibandronate improves hyperphosphatemia in dialysis patients with hyperparathyroidism.

  International urology and nephrology 20040101

• Injectable drug dampens bone loss.

  Health news (Waltham, Mass.) 20031201

• Is ibandronate effective in multiple myeloma?

  European journal of haematology 20031201

• Use of highly potent bisphosphonates in the treatment of osteoporosis.

  Current osteoporosis reports 20031201

• Bisphosphonates in children with bone diseases.

  The New England journal of medicine 20031120

• Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth.

  International journal of cancer 20031110

• Ibandronate: new options in the treatment of osteoporosis.

  Drugs of today (Barcelona, Spain : 1998) 20031101

• Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.

  Annals of the rheumatic diseases 20031001

• The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status.

  Bone 20031001

• Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.

  The Journal of clinical endocrinology and metabolism 20031001

• Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20031001

• The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.

  Toxicology 20030930

• Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030901

• Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20030801

• Oral weekly ibandronate prevents bone loss in postmenopausal women.

  Journal of internal medicine 20030801

• Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.

  Aging clinical and experimental research 20030801

• Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years.

  Journal of endocrinological investigation 20030801

• The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoid cells by enhanced ABCA1 transcription.

  Biochemical and biophysical research communications 20030718

• Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20030701

• Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate.

  Cancer research 20030615

• Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.

  Rheumatology (Oxford, England) 20030601

• Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.

  Bone 20030601

• Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.

  International journal of clinical practice 20030601

• Effects of ibandronate on inflammation in mouse antigen-induced arthritis.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20030501

• The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.

  Bone 20030401

• Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.

  Alimentary pharmacology & therapeutics 20030315

• Review of ibandronate in the treatment of osteoporosis.

  Expert opinion on pharmacotherapy 20030301

• Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20030201

• Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.

  Bone 20030101

• Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.

  European journal of haematology 20030101

• Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.

  Clinical therapeutics 20030101

• Bisphosphonates in the management of metastatic prostate cancer.

  Oncology 20030101

• [Effects of ibandronate on the osteopenia process in tail-suspended rats].

  Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine 20030101

• Treatment of hypercalcemia of malignancy with bisphosphonates.

  Seminars in oncology 20021201

• Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

  Cancer research 20021115

• The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption.

  Calcified tissue international 20021001

• The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.

  Breast cancer research and treatment 20021001

• Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.

  The Journal of rheumatology 20021001

• Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation.

  Transplantation proceedings 20020901

• Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020701

• Novel therapeutic options for osteoporosis.

  Current opinion in rheumatology 20020701

• Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.

  Annals of the rheumatic diseases 20020601

• Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.

  Journal of endocrinological investigation 20020601

• Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020501

• Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats.

  The Journal of rheumatology 20020501

• Bisphosphonates for prevention of postmenopausal osteoporosis.

  Danish medical bulletin 20020201

• Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat.

  Bone 20020101

• Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis.

  Bone 20020101

• Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion.

  In vivo (Athens, Greece) 20020101

• Ibandronate in the treatment of prostate cancer associated painful osseous metastases.

  Prostate cancer and prostatic diseases 20020101

• Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20011001

• [Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma].

  Praxis 20010920

• Effect of ibandronate on bone loss and renal function after kidney transplantation.

  Journal of the American Society of Nephrology : JASN 20010701

• The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.

  Cancer research 20010601

• Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.

  Arteriosclerosis, thrombosis, and vascular biology 20010501

• Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.

  Experimental hematology 20010401

• Bisphosphonates induce breast cancer cell death in vitro.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20001101

• Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 19980401